Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by on Jul 20th, 2026

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $143.40.

A number of equities analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. CLSA set a $146.00 price target on Mirum Pharmaceuticals in a research report on Monday, June 15th. Wolfe Research started coverage on Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target for the company. Finally, Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th.

Read Our Latest Stock Analysis on Mirum Pharmaceuticals

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total transaction of $326,520.00. Following the completion of the sale, the senior vice president owned 3,114 shares of the company’s stock, valued at approximately $373,680. This trade represents a 46.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 65,315 shares of company stock worth $6,991,928 over the last ninety days. 8.32% of the stock is currently owned by company insiders.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB boosted its position in shares of Mirum Pharmaceuticals by 1.6% in the second quarter. Handelsbanken Fonder AB now owns 197,179 shares of the company’s stock worth $23,084,000 after buying an additional 3,179 shares during the period. Contravisory Investment Management Inc. grew its holdings in shares of Mirum Pharmaceuticals by 2.3% during the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after buying an additional 103 shares in the last quarter. Glenmede Trust Co. NA raised its position in Mirum Pharmaceuticals by 66.9% during the first quarter. Glenmede Trust Co. NA now owns 5,532 shares of the company’s stock valued at $511,000 after buying an additional 2,217 shares during the period. Janus Henderson Group PLC raised its position in Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after buying an additional 880,505 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in Mirum Pharmaceuticals in the 1st quarter worth about $573,000.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRM opened at $118.86 on Monday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.99 and a current ratio of 2.09. The stock has a market capitalization of $7.25 billion, a price-to-earnings ratio of -8.73 and a beta of 0.48. Mirum Pharmaceuticals has a 1-year low of $50.25 and a 1-year high of $130.00. The company has a 50 day moving average price of $107.97 and a 200 day moving average price of $99.22.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million during the quarter, compared to the consensus estimate of $148.21 million. During the same period in the prior year, the company posted ($0.30) EPS. Mirum Pharmaceuticals’s quarterly revenue was up 43.3% on a year-over-year basis. On average, research analysts anticipate that Mirum Pharmaceuticals will post -2.01 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

Featured Articles

Analyst Recommendations for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.